ストックスクリーナーアプリを入手
0.5393
1.68%
0.0089
前日終値:
$0.5304
開ける：
$0.59
24時間の取引高:
314.84K
Relative Volume:
0.07
時価総額：
$20.85M
収益：
-
当期純損益:
$-117.67M
株価収益率:
-0.1745
EPS:
-3.09
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
+1.37%
1か月 パフォーマンス:
-6.37%
6か月 パフォーマンス:
-82.66%
1年 パフォーマンス:
-81.27%
1日の値動き範囲:
$0.5056
$0.59
1週間の範囲:
$0.5056
$0.59
52週間の値動き範囲:
$0.4115
$4.2984
Athira Pharma Inc Stock (ATHA) Company Profile
名前
Athira Pharma Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.5393 | 20.85M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Athira Pharma Inc (ATHA) 最新ニュース
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St
Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review
Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews
Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient
Athira to pay $4M to resolve research misconduct allegations - BioWorld Online
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN
Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN
Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360
Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com
Bothell pharma company to pay $4 million over falsified research claims - MSN
Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law
Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa
Athira Pharma CEO sells shares worth $14,107 - Investing.com
Athira Pharma VP of Finance Sells Shares for $1,618 - Investing.com India
Athira Pharma VP of Finance Sells Shares for $1,618 By Investing.com - Investing.com Canada
Athira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News Summary - Benzinga
JMP Securities Downgrades Athira Pharma (ATHA) - MSN
Athira Pharma Insider Ups Holding By 111% During Year - Yahoo Finance
Athira Pharma's SWOT analysis: stock faces challenges after trial setback - Investing.com India
Athira Pharma's SWOT analysis: stock faces challenges after trial setback By Investing.com - Investing.com Canada
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - The Manila Times
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND - GlobeNewswire
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by GSA Capital Partners LLP - Defense World
Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail
Athira Pharma's SWOT analysis: stock shifts focus after trial setback By Investing.com - Investing.com UK
Athira Pharma's SWOT analysis: stock shifts focus after trial setback - Investing.com
Athira Pharma’s Regulatory Compliance Challenges Threaten Drug Development Pipeline - MSN
Athira exploring strategic alternatives after Alzheimer’s failure - BioPharma Dive
Athira Pharma Reports Q3 2024 Financial Results - TipRanks
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - The Manila Times
What You Didn’t Know About Athira Pharma Inc (NASDAQ: ATHA) This Week - Stocks Register
Errors Lower Fee Award For Athira Pharma Investors' Counsel - Law360
US Penny Stocks: November 2024's Top Picks To Consider - Simply Wall St
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - Benzinga
Perceptive Advisors LLC Acquires Significant Stake in Athira Pha - GuruFocus.com
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - MSN
Athira Pharma to Present Results from Phase 2/3 LIFT-AD - GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting - StockTitan
Athira Pharma faces Nasdaq delisting over share price - Investing.com
A closer look at Athira Pharma Inc (ATHA)’s stock price trends - US Post News
A year in review: Athira Pharma Inc (ATHA)’s performance in the last year - US Post News
A Guide To The Risks Of Investing In Athira Pharma Inc (ATHA) - Knox Daily
Analytical Overview: Athira Pharma Inc (ATHA)’s Ratios Tell a Financial Story - The Dwinnex
Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World
Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com
Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com
Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada
Athira Pharma Inc (ATHA) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):